SURMOUNT-5 Trial Summary: Tirzepatide vs Semaglutide

SURMOUNT-5 addressed the comparison patients were already making long before the evidence arrived: tirzepatide or semaglutide? At 72 weeks, mean percentage change in body weight was -20.2% with tirzepatide and -13.7% with semaglutide. [1]

That is a meaningful difference, but it needs interpretation. Headline superiority is not the same as universal superiority for every patient.

What the trial showed

Tirzepatide produced greater average weight loss than semaglutide, and more participants achieved larger thresholds such as 25% reduction in body weight. [1] In practical terms, the study confirmed what many clinicians suspected from earlier indirect comparisons and from SURPASS-2 in diabetes: tirzepatide is generally the more potent weight-loss agent. [1,2]

What most articles miss

Potency is not the same as suitability. The better drug on average is not always the better drug for the individual in front of you. The trial does not erase the importance of tolerability, cost, access, supply, patient preference, adherence, and the broader care model around the medication.

Even head-to-head superiority does not answer the maintenance question. A stronger descent tells you nothing guaranteed about the landing.

The result also should not be reduced to brand tribalism. The clinically serious reading is that the dual GIP/GLP-1 mechanism appears to shift average weight loss further than GLP-1 alone in this setting. [1] A weaker result for semaglutide does not make semaglutide weak. A mean 13.7% reduction at 72 weeks remains clinically significant. [1]

What this means in practice

SURMOUNT-5 helps patients who are deciding between agents, or who are asking whether switching therapy might be justified after a partial response. It also matters for how clinics present treatment. A serious clinic should not pretend these drugs are interchangeable when direct comparative evidence suggests otherwise.

But the study should not be read as a command to switch everyone to tirzepatide. Some patients do very well on semaglutide, tolerate it better, prefer its rhythm, or are already using it within a coherent broader plan. If you want a clinical review of whether your current treatment choice still makes sense, that is exactly what a GLP-1 review addresses.

When to involve your clinician

Before switching agents, especially if other glucose-lowering drugs, significant gastrointestinal side effects, blood-pressure changes, or hydration problems are already in play. [3,4]

Bottom line

SURMOUNT-5 confirmed that tirzepatide outperformed semaglutide on average for weight loss in obesity. That matters. But the more interesting clinical question is not which brand wins the headline. It is which patient needs which trade-off, and what plan exists after the initial descent. [1]